12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actemra regulatory update

FDA accepted for review an sBLA from Roche's Genentech Inc. unit to update the label for Actemra tocilizumab to include treatment of moderate to severe active rheumatoid arthritis in patients who have responded to, or who were intolerant to, previous therapy with >=1...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >